This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Everolimus is an immunosuppressant that was approved for its medical use on 30th March 2009.
Mechanism of Action of undefined
It contains the active ingredient everolimus, which inhibits the activity of a protein called mammalian target of rapamycin (mTOR), which regulates cell growth. This drug can slow the growth of abnormal cancer cells by blocking the mTOR protein. Everolimus helps to reduce the size of tumours and improve outcomes in patients.
Uses of undefined
Everolimus has been developed to treat advanced hormone receptor-positive breast cancer, pancreatic cancer (pancreatic neuroendocrine tumour), and neuroendocrine tumour of the stomach, lung, and intestine that cannot be treated with surgery.
undefined Drug administaration and Dosage available
Your doctor will decide the dose and duration of everolimus based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet at the same time every day, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water. If you forgot to take the tablet, simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.
Warnings, Precautions and Side Effects of undefined
Contact your doctor immediately if you experience shortness of breath, chest pain, or worsening cough. During the everolimus treatment, your doctor may periodically monitor your white blood cell counts, platelets, blood sugar, electrolytes, and kidney parameters to prevent serious complications. This medicine has the potential to cause kidney problems. Report to your doctor if you have been diagnosed with liver disorders, kidney problems, heart failure, high blood cholesterol levels, or hypertension before starting this treatment.
Everolimus tablets have the tendency to cause harm to the unborn foetus. Inform your healthcare provider before starting this treatment if you are pregnant, or have a partner who can become pregnant. Your health care provider will conduct a pregnancy test before you start treatment with everolimus Tablet. Discuss effective birth control methods with your healthcare provider and use them during treatment and for 8 weeks after your last dose. It is not known if everolimus passes into breast milk. Hence, it is not recommended to breastfeed during this treatment.
The common side effects that are likely to occur while you are on the treatment with everolimus are fever, chills, skin Rash, joint pain, swelling, tiredness, loss of appetite, high risk of infection, mouth ulcers, and difficulty breathing. If you experience any allergic reactions such as rashes, itching, hive, flushing, chest pain, dizziness, trouble breathing, or swallowing. report to your doctor immediately.
Word Of Advice
Avoid driving or operating heavy machinery if you experience dizziness or any discomfort during treatment with Everolimus Tablet. The occurrence of mouth ulcers or sores is pretty common during this treatment, so your healthcare provider will prescribe a mouthwash.
Frequently Asked Question
- Accord Healthcare Limited, Electronic medicines compendium (EMC), [ Revised on Oct 2020] [ Accessed on 18th March 2023], https://www.medicines.org.uk/emc/files/pil.11084.pdf
- Jan Hasskarl; Everolimus; Recent Results in Cancer Research; Published on 2018; Accessed on 18/03/2023; https://pubmed.ncbi.nlm.nih.gov/30069763/
- Novartis Pharmaceuticals Corporation, US Food and Drug Administration, [ Revised on July 2012] [ Accessed on 18th March 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Targeted therapy: tyrosine kinase inhibitors, monoclonal antibodies and cytokines, 12th edition, 2011, 1743.
- KD Tripathi, Essentials of Medical Pharmacology, Immunosuppressant drugs, 7th edition, 2013, 878 - 882.
The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.